Introduction

Pegasus not only has exclusive rights of the above disclosed patent inventions, but also has secret, non-public know-how technologies, that is, other than the patented technologies relating to manufacturing processes, as well as the application of industrial technology and knowledge, that is technical secrets (Know-How). Proprietary technology, as the key indicators of international technical trade in the modern intellectual property system, has huge economic benefits including intellectual property rights. Pegasus proprietary and know-how technologies are a combination of patents, technical know-how and exclusive rights. While patent applications are granted or pending, using Know-How can keep confidentiality of certain technologies. These patented and know-how technologies are a group of intellectual properties that patent technology is not able to be transferred without know-how technologies.

Several patents based on SMCD have been filed PCT applications to US, Canada, EU, Singapore, China, and India. "NOVEL DAMMARANE SAPOGENINS, THEIR USE AS ANTI-CANCER AGENTS, AND A PROCESS FOR PRODUCING SAME" has granted patent from US (US6888014B2、US6949523B2), EU (UK, Germany, France, European patent No.1414843), Singapore (P-No.95428), and China (ZL02817551.4) since 2005. "PROTOPANAXADIOL AND PROTOPANAXATRIOL AND THEIR USE AS ANTI-CANCER AGENTS" has granted patent from Singapore (P-No.96495) in 2006 and China (ZL02817551.4) in 2007. "SAPONINS AND SAPOGENINS FOR USE IN COMBINATION THERAPY FOR CANCER" has granted patent from China (ZL03819192.X) in 2008. Key components of the SMCD technology have been filed for patent in 2004. The in-process control of SMCD, including phytochemistry extraction and isolation, drug candidates discovery, combination rationale and chemical profiling, manufacturing process optimization and standard operation practices, has most important knowledge secrets that cover manufacturing and purification process for metabolites and formulation. The technology makes possible to extract and isolate the trace (ppm) active ingredients from the herb in a large-scale production cost-effectively and practically and establishes the natural product selective metabolites manufacturing process. Pegasus currently has exclusive intellectual property for manufacturing process of several APIs and botanical drug substances such as aPPD, aPPT, PAM120, PBM110, PBM100 and PBD1226, PBD2131, PBD1370.

Based on OBET, "METHOD OF INCREASING IN-STOMACH BIOAVAILABILITIES OF SAPONINS, SAPOGENINS, AND THEIR COMPOSITIONS AND USES THEREOF" (China 200410084849.8) and "METHOD, FORMULATION, AND USE THEREOF FOR IMPROVED ORAL ABSORPTION OF PHARMACEUTICALS OR NUTRIENTS" (China 200510067126.1) are pending patents. However, some know-how secrets implied can overcome challenges facing soluble drugs from degradation, enzymatic modification, and crystallized precipitation, and protect the ingredients in their intact molecular form from effects of gastric-intestinal fluids and increasing stomach absorption as opposed to intestine absorption. Advancing absorption in the upper digestive tract minimizes the ingredients' contact with digestive fluids and prevents the modification of the ingredients into medicinally inactive substances. Eventually, the intact drug pharmacological action is expected.
Based on leading successfully mapped all specific epitopes of SARS Corona Virus by PEP-HIT, a patent "Novel peptides and their uses in Diagnosis, Treatment, and Prevention of Corona Virus related Severe Acute Respiratory Syndrome (SARS) Diseases" (China 200910047892.X) is pending. Using high-throughput peptide array screening and proteomic informatics, the identified peptides and/or their derivatives for detecting antibodies in biological samples of SARS patients can develop diagnosis reagents as well as safe and effective SARS peptide vaccines. Most importantly, high-throughput peptide array screening and proteomic informatics lead Pegasus to be more time-efficient in drug candidates discovery, pharmacological action targets screening and clinical diagnostic applications than other companies.

Pegasus R & D diversity and capability not only continuously make innovative and exclusive technologies available, but also lead Pegasus products marketing exclusively and competitively.